Since 2020, Jeffrey A. Bailey has served as Chairman of the Board at Tekla Capital Management, a registered investment adviser, based in Boston, with four, multi-billion dollar, closed-end funds that predominately invest in the securities of public and private healthcare companies. He has also been Chairman of the Board of Aileron Therapeutics since 2017.
Mr. Bailey has significant pharmaceutical and biotech leadership experience, with expertise in supply chain, commercial, finance, business development, and product development. He has deep experience managing shareholder expectations and company objectives to achieve a successful outcome. Mr. Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and Fougera Pharmaceuticals (2011-2012).
From 2010 to 2011, Mr. Bailey served as Chief Commercial Officer at King Pharmaceuticals, where he led more than 750 employees delivering more than $1.5 billion in annual sales. From 2008 to 2010, Mr. Bailey was President and General Manager at Novartis, where he led a 1000-member primary care and specialty pharma team delivering more than $825 million in sales.
Mr. Bailey began his career in 1984 at the Johnson & Johnson Family of Companies where he earned successive leadership roles over the course of 20 years. He holds a degree in Business Administration from Rutgers University in New Brunswick, NJ.
What is Jeffrey Allen Bailey's net worth?
The estimated net worth of Jeffrey Allen Bailey is at least $107,382.24 as of November 11th, 2024. Mr. Bailey owns 13,356 shares of Aurinia Pharmaceuticals stock worth more than $107,382 as of March 31st. This net worth estimate does not reflect any other assets that Mr. Bailey may own. Learn More about Jeffrey Allen Bailey's net worth.
How do I contact Jeffrey Allen Bailey?
The corporate mailing address for Mr. Bailey and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at ir@auriniapharma.com. Learn More on Jeffrey Allen Bailey's contact information.
Has Jeffrey Allen Bailey been buying or selling shares of Aurinia Pharmaceuticals?
Jeffrey Allen Bailey has not been actively trading shares of Aurinia Pharmaceuticals during the last quarter. Most recently, Jeffrey Allen Bailey sold 4,557 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a transaction totalling $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares of the company's stock, valued at $112,591.08. Learn More on Jeffrey Allen Bailey's trading history.
Who are Aurinia Pharmaceuticals' active insiders?
Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Aurinia Pharmaceuticals?
In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 366,704 shares worth more than $2,888,411.85. The most recent insider tranaction occured on March, 7th when insider Greg Keenan sold 8,305 shares worth more than $68,350.15. Insiders at Aurinia Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Aurinia Pharmaceuticals. Information on this page was last updated on 3/7/2025.
